Author: Marie Benz MD FAAD

[caption id="attachment_74143" align="aligncenter" width="500"]Conceptual illustration of AAV9-mediated delivery of the WWOX gene to neurons Conceptual illustration of AAV9-mediated delivery of the WWOX gene to neurons, representing the first clinical use of a gene replacement therapy designed to restore WWOX function in the brain of an infant with WOREE syndrome.Credit: Hebrew University of Jerusalem / AI-generated illustration[/caption] MedicalResearch.com Interview with: Prof. Rami Aqeilan Jacob M. Eisenberg and Thomas W. Baylek Chair for Medical Research in the field of Genetic Engineering Lautenberg Center for Immunology and Cancer Research Faculty of Medicine Hebrew University of Jerusalem Jerusalem, Israel This therapy is based on more than a decade of research led by Prof. Rami Aqeilan, brought together with scientists, clinicians, and biotechnology leaders from Israel and the United States, including Dr. Naama Orenstein and Dr. Dror Kraus of Schneider Children's Medical Center and Dr. Yael Weiss, CEO of Mahzi Therapeutics.
MedicalResearch.com: What is the background for this study? Would you briefly explain the functions of the WWOX gene? Response: WWOX (WW domain-containing oxidoreductase) is a highly conserved gene that plays essential roles in brain development, neuronal function, and cellular stress responses. Nearly two decades ago, our laboratory and others began studying WWOX because of its involvement in cancer biology. However, over the past decade it became increasingly clear that WWOX is also critical for normal brain development. Inherited loss-of-function mutations in WWOX cause a devastating neurological disorder known as WOREE syndrome (WWOX-Related Epileptic Encephalopathy). Affected children typically develop severe, treatment-resistant epilepsy during infancy, profound developmental delay, intellectual disability, and significant motor impairment. Unfortunately, there has been no disease-modifying therapy available for these patients. The foundation for this therapeutic approach came from years of fundamental research in our laboratory aimed at understanding the biological role of WWOX in the nervous system. Using genetically engineered mouse models, we discovered that deleting WWOX specifically in neurons was sufficient to reproduce the major neurological features observed in mice lacking WWOX throughout the entire body. This finding demonstrated that neuronal WWOX deficiency is a primary driver of the disease and suggested that restoring WWOX function in neurons might be sufficient to achieve therapeutic benefit. Based on this insight, we developed a gene replacement strategy designed to restore WWOX expression selectively in neurons using an adeno-associated viral (AAV) vector. In preclinical studies, delivery of this vector into the brains of WWOX-deficient mice resulted in remarkable rescue of the disease phenotype. Treated animals exhibited normal behavior, elimination of seizures, and substantial correction of the neurological abnormalities associated with WWOX deficiency. These findings provided the critical proof-of-concept that neuronal gene replacement could effectively reverse key features of the disease and laid the scientific foundation for translating this approach toward clinical application in patients with WOREE syndrome.

MedicalResearch.com Interview with: [caption id="attachment_74139" align="alignleft" width="160"]John James (JJ) Parker, MD, MSAssistant Professor, Department of Pediatrics and Medicine Feinberg School of Medicine, Northwestern University Attending Physician, Division of Advanced General Pediatrics & Primary Care Lurie Children's Hospital of Chicago Attending Physician, Transitional Care Clinic, Northwestern Medical Group Chicago, Illinois 60611 Dr. Parker[/caption] John James (JJ) Parker, MD, MS Assistant Professor, Department of Pediatrics and Medicine Feinberg School of Medicine, Northwestern University Attending Physician, Division of Advanced General Pediatrics & Primary Care Lurie Children's Hospital of Chicago Attending Physician, Transitional Care Clinic, Northwestern Medical Group Chicago, Illinois 60611   MedicalResearch.com: What is the background for this study? What are the main findings? Response: Fathers are a critical but overlooked population. We know the health of fathers influences the health of their families and there is growing evidence that fatherhood influences men's health, but studies from the US are lacking. This study used data from the Coronary Artery Risk Development in Young Adults (CARDIA) study, which is a cohort study that has followed young adults for 35 years, allowing us to measure associations of fatherhood with health during the life course of men. We found multiple associations between fatherhood and men's health, and our outcomes differed by race. Black fathers had lower death rates than Black nonfathers, which we did not detect in White men. For both Black and White men, becoming a father at less than 25 was associated with poor health outcomes. For Black men early entry to fatherhood was associated with higher mortality rates and for White men it was associated with worse cardiovascular health.

MedicalResearch.com Interview with: [caption id="attachment_74111" align="alignleft" width="92"]Luis A. Rodriguez, PhD, MPH, RDResearch Scientist, Kaiser Permanente Northern California Division of Research Assistant Professor, Department of Health System Sciences Kaiser Permanente Bernard J. Tyson School of Medicine Assistant Adjunct Professor, Department of Epidemiology & Biostatistics University of California, San Francisco Dr. Rodriguez[/caption] Luis A. Rodriguez, PhD, MPH, RD Research Scientist, Kaiser Permanente Northern California Division of Research Assistant Professor, Department of Health System Sciences Kaiser Permanente Bernard J. Tyson School of Medicine Assistant Adjunct Professor, Department of Epidemiology & Biostatistics University of California, San Francisco ADA 2026 Poster Presentation: Machine-Learning Modeling for T2DM Prediction in over 3 Million Adults American Diabetes Association 85th Scientific Sessions, June 2026
MedicalResearch.com: What is the background for this study? What are the risk factors used to develop the prediction model? Response: Type 2 diabetes develops gradually over many years, often without clear warning signs. As a result, it can be difficult for health systems to identify which adults are most likely to benefit from prevention efforts before the disease develops. In this study, we used electronic health record data from more than 3 million adults in Kaiser Permanente Northern California to develop a prediction model that estimates an individual's risk of developing type 2 diabetes over 1, 3, and 10 years. The model is based on information routinely collected during clinical care, including age, sex, race/ethnicity, body mass index, blood glucose levels, smoking, physical activity, medical and family history, and medication use. By combining these clinical, biological and behavioral factors, the model provides a more comprehensive assessment of diabetes risk than traditional screening approaches.

[caption id="attachment_74104" align="alignleft" width="200"]dr_avishek_kumar Dr. Avishek Kumar[/caption] MedicalResearch.com Interview with: Avishek Kumar, MD Board-Certified Medical Oncologist and Hematologist Edison, NJ (NYC Metro) MedicalResearch.com: What is the background for this announcement? Response: Pancreatic cancer has been one of the hardest cancers to treat in all of oncology. It is often found late. It spreads early. For decades, it has not had the kind of breakthroughs we have seen in lung cancer, melanoma, breast cancer, or other tumors. In the majority of patients with advanced pancreatic cancer, treatment has mostly meant chemotherapy. Regimens like FOLFIRINOX or gemcitabine/nab-paclitaxel can help. They can extend life. They can shrink cancer. But the benefit is often limited, and the side effects can be tough. Once the cancer grows after first-line treatment, the options get even more narrow. That is why the daraxonrasib data matter. Daraxonrasib, also known as RMC-6236, is an investigational oral targeted drug. It is designed to block active RAS signaling. That is a big deal because pancreatic cancer is one of the most RAS-driven cancers we see. Most pancreatic cancers have a KRAS mutation or another alteration in that pathway. For years, KRAS was considered "undruggable." We knew it was driving the cancer. We just did not have a good way to hit it. This new data suggests that may be changing. In previously treated advanced RAS-mutated pancreatic cancer, daraxonrasib appeared to improve median overall survival compared with standard chemotherapy. Reports have described survival of about 13.2 months versus 6.7 months. In pancreatic cancer, that is not a small finding. That is meaningful. Very meaningful.

[caption id="attachment_73991" align="aligncenter" width="500"]itemized medical bills Source[/caption] Want to get the most out of your injury compensation claim? The majority of injury victims make the same expensive error. They give the insurance company sloppy paperwork and hope they play nice. Spoiler: they don't. Your itemized medical bill is your most powerful negotiating tool. It's the difference between a lowball demand and the full amount you should receive. The good news is that your medical bill already exists, sitting in your provider's office right now. Here's what's coming up: Why Itemized Medical Bills Matter So Much What An Itemized Bill Actually Includes How Documentation Boosts Your Settlement Don't Miss Your Filing Deadline

[caption id="attachment_73932" align="aligncenter" width="500"]AI in Mental Health pexels Photo by cottonbro studio[/caption] Editor's note: This piece discusses mental health issues. If you have experienced suicidal thoughts or have lost someone to suicide and want to seek help, you can contact the Crisis Text Line by texting "START" to 741-741 or call the Suicide Prevention Lifeline at 800-273-8255. The application of artificial intelligence (AI) in mental health care is growing, providing novel solutions to the diagnosis, tracking, and management of mental health conditions. AI has great potential to increase the efficiency and accessibility of mental health care, from chatbots that offer emotional support to tools that identify early indicators of depression and anxiety. But these advantages also come with significant risks and ethical issues such as emotional safety, accuracy, and privacy. The possibilities and difficulties of AI in mental health are examined in this article, emphasising the necessity of its ethical and responsible application.

Editor's note: This piece discusses mental health issues. If you have experienced suicidal thoughts or have lost someone to suicide and want to seek help, you can contact the Crisis Text Line by texting "START" to 741-741 or call the Suicide Prevention Lifeline at 800-273-8255. [caption id="attachment_73822" align="alignleft" width="200"]Hampus Yngwe, MD, MScCentre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, and Stockholm Health Care Services Stockholm, Sweden Dr. Hampus Yngwe[/caption] MedicalResearch.com Interview with: Hampus Yngwe, MD, MSc Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, and Stockholm Health Care Services Stockholm, Sweden MedicalResearch.com: What is the background for this study? Response: Depression is a common and disabling condition and current treatments do not work for all patients. Psilocybin has shown promise as a rapid-acting treatment, but more controlled studies are needed to clarify its effects, durability and safety.

MedicalResearch.com Interview with:

Nimit Desai, BA Medical Student and Affiliate Researcher UC San Diego School of Medicine and Qualcomm Institute John W. Ayers, PhD, MA Vice Chief of Innovation, Head of AI, and Professor UC San Diego School of Medicine, Altman Clinic and Translational Research Institute, and Qualcomm Institute Christopher Horvat, MD, MHA, MSIT Associate Professor of Critical Care Medicine, Pediatrics, Biomedical Informatics, and Clinical & Translational Science Associate Director, Safar Center for Resuscitation Research More than 350,000 Americans go into cardiac arrest outside a hospital every year, yet only about 2% of the population is certified in CPR. When someone collapses, most bystanders call 911 and wait — and even when dispatchers walk callers through CPR instructions, it often takes nearly three minutes before chest compressions begin. Researchers at UC San Diego set out to close that gap with AI. The result is ChatCPR, an open-source AI system built on actual 911 dispatcher training protocols and decades of CPR evidence. In head-to-head comparisons using real, de-identified 911 calls, ChatCPR outperformed human dispatchers on every measure — scoring 15 percentage points higher on basic steps and 36 points higher on advanced steps.

MedicalResearch.com: What is the background for this study?

Response: There are over 178,000 published articles about AI in medicine. But "when will AI actually save lives?" We didn't have a good answer. So that question became the starting point. We looked at where AI could make the biggest immediate difference, not in documentation or billing or any of that, but in a moment where seconds literally determine whether someone lives or dies. And the answer was obvious: out-of-hospital cardiac arrest. More than 350,000 Americans go into cardiac arrest outside a hospital every year. Yet, only about 2% of us are certified in CPR. When someone collapses from an arrest, most people just call 911 and wait, and wait, and wait. And even when dispatchers eventually walk callers through CPR instructions, they're juggling multiple tasks and it often takes nearly 3 minutes before chest compressions even start. We thought AI could close that gap.

Losing stubborn pockets of fat through diet and exercise is genuinely difficult. These areas, common around the abdomen, thighs, flanks, and upper arms, are often the last to respond and the first to return, which has driven significant research interest in non-surgical body contouring over the past decade. Cryolipolysis, more commonly known as fat freezing, has emerged as one of the most studied and widely adopted of these treatments. Here is a clear look at how it works, what the evidence shows, and what to consider before pursuing it.

What Is Cryolipolysis?

Cryolipolysis is a non-invasive procedure that uses controlled cooling to selectively target and destroy fat cells beneath the skin. The technology was developed by dermatologists at Harvard Medical School, Dr. Dieter Manstein and Dr. R. Rox Anderson, who observed that fat cells are significantly more vulnerable to cold temperatures than the surrounding skin, nerves, and muscle tissue. This selective sensitivity is the foundation of the treatment. By applying precise cooling to a targeted area, fat cells can be disrupted without damaging the tissue around them.

How It Works

During a cryolipolysis session, a device applicator is placed on the treatment area and draws the tissue between two cooling panels. It then applies a controlled temperature, typically between -9 and -11 degrees Celsius, for a period of 35 to 60 minutes depending on the applicator used. The cooling triggers a process called apoptosis in the fat cells, a form of natural, programmed cell death. Over the following weeks, the body's lymphatic system gradually processes and eliminates those dead fat cells. This is why results appear progressively rather than immediately after treatment.

What the Research Shows

Clinical studies have consistently shown that a single cryolipolysis session reduces the fat layer in the treated area by approximately 20 to 25 percent. A 2015 review published in Aesthetic Surgery Journal examined multiple clinical studies and found the treatment to be both effective and well-tolerated across a range of body areas. The FDA cleared cryolipolysis for use in the United States in 2010, with successive clearances expanding the list of approved treatment areas. Results are considered permanent in the sense that treated fat cells do not regenerate, though significant weight gain can still affect remaining fat cells in the area.

fat freezing scienceWho Is a Good Candidate?

Cryolipolysis is not a weight loss treatment. It is a body contouring procedure designed for people who are at or near a healthy weight but have localised areas of fat that have not responded to diet and exercise. The best candidates are those with pinchable fat in specific areas rather than diffuse, generalised weight gain. People with certain medical conditions, including cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria, are not suitable candidates and should discuss their full history with a qualified medical professional before considering the procedure. Pregnancy, active skin conditions in the treatment area, and open wounds also rule out cryolipolysis until those conditions are fully resolved.

What to Expect Before, During, and After

A proper initial consultation should include a clinical assessment of whether the patient is a genuine candidate, an explanation of what the treatment can and cannot achieve, and a clear outline of any risks. Clinics that skip or rush this step are not operating to a standard worth trusting. During the session itself, most patients describe the first few minutes as intensely cold, with pressure from the applicator. The area typically becomes numb within ten minutes, after which the rest of the treatment is quite comfortable. Most people use the time to read, use their phone, or rest. After the device is removed, the treated area is briefly massaged to help break down the crystallised fat cells. Clinical evidence suggests this post-treatment massage can improve the final result. Common side effects include temporary redness, bruising, localised numbness, and tingling, most of which resolve within a few weeks.

How to Choose the Right Clinic

The outcome of a cryolipolysis treatment depends as much on the clinic and practitioner as it does on the technology itself. Medical-grade equipment, trained staff, and a thorough consultation process all directly affect both safety and results. When evaluating providers, look for clinics that assess candidacy honestly, explain realistic outcomes, and take time to address questions without pressure. A clinic willing to tell you when cryolipolysis is not the right fit is one that can be trusted when they say it is. Body Catalyst is widely regarded as the best fat freezing clinic for women seeking non-invasive body contouring in Australia. The clinic operates with a medically informed approach and a process built around individual assessment, rather than applying a generic treatment plan to every patient who walks through the door.

fat-freezing-what-to-expect

Results and What to Expect Over Time

Most patients begin to notice visible changes around three weeks after treatment, with full results typically appearing between eight and twelve weeks as the body continues to process treated fat cells. Some individuals benefit from more than one session, particularly for larger or more stubborn areas. Maintaining a stable weight after treatment helps preserve the result. Cryolipolysis permanently removes a percentage of fat cells from the treated area, but significant weight gain can cause remaining cells to expand, which reduces the visible benefit over time. General lifestyle factors, including regular physical activity and a balanced diet, remain relevant even after treatment. The procedure removes fat cells, but it does not change the habits that influence overall body composition in the longer term.

MedicalResearch.com: What is the background for this study? Would you describe what is meant by FAST spine MRI? Does it require any new technology or learning curve?

 
Response: Full sequence spine MRIs are routinely performed as screening studies in pediatric patients with idiopathic scoliosis; however, they may take up to 60 minutes or require sedation. Limited sequence or "FAST" spine MRI scans require less time and a less frequent need for sedation, but they may decrease diagnostic accuracy. Limited sequence MRI scans perform fewer imaging sequences compared to full sequence MRI scans. The purpose of this study is to investigate the feasibility and safety of limited sequence MRI scans as a screening tool in patients with idiopathic scoliosis. The learning curve is not steep to become comfortable in evaluating limited sequence spine MRI images or reports.

MedicalResearch.com Interview with: [caption id="attachment_73639" align="alignleft" width="125"]Bernard F. Fuemmeler, PhD, MPHProfessor and Gordon D. Ginder, MD Chair in Cancer Research Associate Director of Population Science, Massey Comprehensive Cancer Center Director of Research, Family Medicine and Population Health Dr. Fuemmeler[/caption] Bernard F. Fuemmeler, PhD, MPH Professor and Gordon D. Ginder, MD Chair in Cancer Research Associate Director of Population Science, Massey Comprehensive Cancer Center Director of Research, Family Medicine and Population Health [caption id="attachment_73640" align="alignleft" width="125"]Kristina L. Tatum, PsyD, MSInstructor Department of Social and Behavioral Sciences School of Public Health Dr. Tatum[/caption] Kristina L. Tatum, PsyD, MS Instructor Department of Social and Behavioral Sciences School of Public Health A large population-based analysis of more than 841,000 breast cancer patients across the United States examines whether GLP-1 receptor agonist use is associated with improved survival and lower recurrence risk — with findings that researchers describe as very promising.
MedicalResearch.com: What is the background for this study? What are the main findings? Response: Glucagon-like peptide-1 receptor agonists, or GLP-1RAs, have been used since 2005 and as the GLP1RAs treatments and delivery methods have improved, their use has markedly increased. Now it is estimated that nearly 1 in 8 US adults report ever using a GLP-1RA, which includes many people who are using them to treat obesity, diabetes, heart disease, and sleep apnea. There has been some preclinical data from mouse models to suggest that maybe GLP1RAs have an anticancer effect reducing the effects of obesity on tumor growth or progression. We were interested to understand to what extent GLP1RA use among cancer patients might be associated with cancer outcomes, like length of survival after cancer treatment or the chance of recurrence. In our large population-based study using an aggregate of de-identified electronic health record data from more than 841,000 patients with breast cancer across the US, we found that GLP-1 RAs use was associated with significantly improved survival and lower recurrence risk among patients with obesity or type 2 diabetes. Among patients with obesity, GLP-1 RAs use was associated with approximately 65% lower risk of death and a 56% lower risk of recurrence over 10 years compared with nonuse. We also observed substantially improved outcomes among patients with type 2 diabetes compared with insulin or metformin.

MedicalResearch.com Interview with: Daniel Pastula MD, MHS
Professor of Neurology, Medicine (Infectious Diseases), and Epidemiology
University of Colorado School of Medicine &
Colorado School of Public Health Daniel Pastula MD, MHS Professor of Neurology, Medicine (Infectious Diseases), and Epidemiology University of Colorado School of Medicine & Colorado School of Public Health Hantavirus infections have drawn renewed attention following recent outbreak reports.  Dr. Pastula explains that hantavirus is not a single disease but a family of viruses with distinct characteristics depending on geographic region and rodent host — and that mortality rates can approach 40% in the most severe form found in the Americas.

Please note: Supplements are generally not FDA tested or approved. Some supplements can interfere with medications including blood pressure meds and anticoagulants. Do not delay seeking medical attention for medical concerns by taking supplements without medical advice. Combining supplements can increase the risk of toxicity and side effects. Statements and product contents have not been independently confirmed by MedicalResearch.com or Eminent Domains Inc. Please discuss any and all supplements you take or are considering taking with your health care provider. Ratings in this post are the opinions of the contributing writer and not MedicalResearch.com or Eminent Domains Inc. GHK-Cu is NOT FDA approved for oral use and is sold for topical use only. Do not use peptides in any form without the express approval of your medical provider. Most injectable or oral peptides are not legally dispensed for non-research purposes.

Copper peptides are gaining traction in skincare and haircare for their ability to revitalize skin and support hair growth. To understand what sets copper peptides apart, it's crucial to examine the scientific research and their growing popularity in beauty routines. A detailed GHK-Cu peptide research guide can help consumers integrate these ingredients more effectively. Designed to work at the cellular level, copper peptides play vital roles in supporting youthful skin and encouraging healthy hair. Exploring the mechanisms behind these compounds offers practical insights for consumers and explains why they are included in many modern formulations.

Editor's note: This piece discusses mental health issues. If you have experienced suicidal thoughts or have lost someone to suicide and want to seek help, you can contact the Crisis Text Line by texting "START" to 741-741 or call the Suicide Prevention Lifeline at 800-273-8255.

Please note: Cannabis laws and regulations vary by state and locality. Cannabis use may have significant health risks, particularly for adolescents, pregnant individuals, and those with a history of mental health conditions. Cannabis has not been approved by the FDA for most uses and may interact with medications. Do not use cannabis as a substitute for medical treatment. The information in this post is for educational purposes only and does not constitute medical or legal advice. Always consult your physician or qualified healthcare provider before making decisions about cannabis use. Do not use cannabis products if pregnant, nursing or may become pregnant.  Children should never be exposed to cannabis products.

MedicalResearch.com Interview with: [caption id="attachment_73658" align="alignleft" width="130"]Prof. Shu-Hong Zhu Prof. Shu-Hong Zhu[/caption] Shu-Hong Zhu, Ph.D. Professor of Family Medicine and Public Health and Director of the Center for Research and Intervention in Tobacco Control (CRITC) University of California, San Diego MedicalResearch.com: What is the background for this study? Response: Cannabis use in the U.S. has steadily increased over recent decades. As use rates increased, perceptions that cannabis use is harmful have trended in the opposite direction. Declining harm perceptions in the broader population are concerning in part because of their influence on adolescents. Regular cannabis use during adolescents can negatively impact overall functioning, cognition, and educational achievement. It can lead to depression, psychosis, and suicidality. If young people don’t perceive cannabis as harmful, they are more likely to use it and suffer these effects. The purpose of this study was to investigate the extent to which adolescents view the everyday and occasional use of cannabis as harmful, and to compare their perceptions of cannabis to their perceptions of alcohol, cigarettes, and nicotine vapes. It used data from over 160,000 students who took the 2019−2020 California Student Tobacco Survey and over 16,000 who took the 2024 California Youth Tobacco Survey.

MedicalResearch.com Interview with: [caption id="attachment_73653" align="alignleft" width="150"]Bailey MilnePhD Graduate Student | Epidemiology
Queen's University | Department of Public Health Sciences
Kingston, ON Bailey Milne[/caption] Bailey Milne PhD Graduate Student | Epidemiology Queen's University | Department of Public Health Sciences Kingston, ON A large population-based study using health administrative data from Ontario examines whether endometriosis is associated with an increased risk of congenital anomalies in offspring — with findings that suggest increased monitoring may be warranted for affected pregnancies.
MedicalResearch.com: What is the background for this study? The study was conducted using health administrative data in Ontario. The data was from 2006 to 2021, which resulted in over 1.4 million mother-baby pairs. Endometriosis is an inflammatory condition where the uterine lining grows outside of the uterus, which can result in painful menstruation, intercourse and bowel movements. Roughly 10% of reproductive aged patients have endometriosis, and of those, 30–60% have infertility.

[caption id="attachment_73601" align="alignleft" width="135"]MedicalResearch.com Interview with:Mythili Menon Pathiyil, MBBS Gastroenterology Fellow SUNY Upstate Medical University Dr. Pathiyil[/caption] MedicalResearch.com Interview with: Mythili Menon Pathiyil, MBBS Gastroenterology Fellow SUNY Upstate Medical University Colorectal cancer mortality is currently the leading cause of cancer-related death in individuals below the age of 50 in the United States. A new analysis presented at DDW 2026 quantifies those patterns and identifies which populations are most at risk — with the goal of informing earlier recognition, targeted screening, and equity-focused prevention.

[caption id="attachment_73589" align="alignleft" width="200"]Teppo Järvinen MD PhDProfessor of Orthopaedics and Traumatology University of Helsinki, HUS Dr. Järvinen[/caption] MedicalResearch.com Interview with: Teppo Järvinen MD PhD Professor of Orthopaedics and Traumatology University of Helsinki, HUS MedicalResearch.com: What is the background for this study? Response: Arthroscopic partial meniscectomy (APM) is one of the most frequently performed orthopedic procedures worldwide, particularly for middle-aged and older patients with knee pain and a degenerative meniscal tear. Over the past 15–20 years, multiple randomized trials have questioned the effectiveness of this procedure, showing no meaningful benefit compared with non-operative care (typically, exercise or physical therapy) or even placebo (sham) surgery in the short to medium term. Our study reports the 10-year follow-up of the FIDELITY trial, a randomized, placebo-surgery controlled trial.

[caption id="attachment_73537" align="aligncenter" width="500"]fix-sleep-fix-diet.jpg Pexels[/caption] You're tracking your food. You're showing up at the gym. The scale isn't moving. The clothes still fit the same. And somewhere underneath the frustration is a quieter symptom you've been ignoring because it doesn't seem related: you haven't actually slept well in months. Here's the part most weight loss conversations skip. The relationship between sleep and weight isn't a wellness slogan. It's a measurable physiological mechanism, and for a meaningful number of people, fixing the sleep is the missing variable that finally lets the rest of the work pay off.

The Mechanisms Are More Specific Than People Realize

Three things happen when sleep is chronically short or fragmented, and they stack.

Hunger Hormones Shift

Two hormones regulate appetite: ghrelin (which says "eat") and leptin (which says "stop"). After even a few nights of restricted sleep, ghrelin rises and leptin drops. The result, measured repeatedly in controlled studies, is that sleep-deprived people eat several hundred extra calories the next day without registering any change in willpower or intention.

Cravings Get More Specific

Sleep loss specifically increases cravings for high-calorie, high-carbohydrate foods. Brain imaging shows reduced activity in the prefrontal cortex (decision-making) and increased activity in reward centers when sleep is short. The food choices feel like preference. They're partly chemistry.

Insulin Sensitivity Drops

Even short stretches of poor sleep reduce insulin sensitivity, meaning the body processes carbohydrates less efficiently and stores more of them as fat. This is one of the more striking findings in recent metabolic research — and it shows up after as little as a week of restricted sleep in otherwise healthy adults.

[caption id="attachment_73528" align="alignleft" width="200"]Dr. Yuval Malka, PhDFaculty of Medicine Hebrew University and
Founder & CEO of Modular Therapeutics BV Dr. Yuval Malka, PhD[/caption] MedicalResearch.com Interview with Dr. Yuval Malka, PhD Faculty of Medicine Hebrew University and Founder & CEO of Modular Therapeutics BV and Dr. William Faller PhD University of Bristol discussing their new study on RNA dicing — a fundamental mechanism that generates multiple functional protein outputs from a single mRNA molecule — and its implications for cancer biology and therapeutics.

MedicalResearch.com: What is the background for this study?

Response: This study is a follow-up to previous work published in recent years (Malka et al., Nature Communications 2017; Malka et al., Molecular Cell 2022), in which we discovered that the mRNA of thousands of genes can be further processed into smaller fragments that translate into shorter proteins. On one hand, this finding helps bridge the gap between our understanding of the transcriptome - traditionally limited to ~20,000 genes and the proteome, which contains hundreds of thousands to potentially millions of distinct protein and peptide isoforms. On the other hand, those earlier studies did not provide sufficient biological insight into this extensive and robust process. The current study represents the third part of this trilogy, introducing a new concept in RNA biology termed "RNA dicing." We show that RNA dicing in eukaryotic systems enables the production of multiple functional protein outputs from a single mRNA molecule. How does this work? Most proteins consist of several domains, each with a distinct function, for example, mediating protein–protein interactions, determining subcellular localization, or carrying catalytic activity. We demonstrate that RNA dicing selectively removes portions of the mRNA template, resulting in the translation of shorter proteins lacking specific domains. This leads to substantial changes in protein function, localization, and interaction partners. In simple terms, RNA dicing mediates modular gene expression.

MedicalResearch.com Interview with a VERTEX Spokesperson discussing suzetrigine (JOURNAVX®), a first-in-class non-opioid pain signal inhibitor, and new Phase 4 data presented at the 2026 Annual Regional Anesthesiology and Acute Pain Medicine meeting.

MedicalResearch.com: What is the background for this study?

Response: There is a critical need for effective, safe non-opioid analgesics to help manage pain and reduce reliance on opioids. Despite significant safety and tolerability concerns such as addiction, opioid use disorder (OUD) and gastrointestinal side effects, opioids remain a common approach for managing moderate-to-severe acute pain. Our recent phase 4, single-arm study assessing suzetrigine in patients who underwent arthroscopic orthopedic procedures or laparoscopic abdominal or gynecological procedures highlighted the transformative potential for suzetrigine to be used as part of an opioid-free multimodal therapy for patients with moderate-to-severe acute pain. JOURNAVX® (suzetrigine) is a first-in-class, prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, including postoperative pain, in adults. It works by selectively inhibiting the NaV1.8 sodium channel on peripheral nociceptors and, therefore, is not believed to have the addiction potential and tolerability issues associated with centrally acting opioids.

[caption id="attachment_73447" align="alignleft" width="142"]Edward Liu, MDGeisinger College of Health Sciences Scranton, PA 18509 Dr. Edward Liu[/caption] MedicalResearch.com Interview with: Edward Liu, MD Geisinger College of Health Sciences Scranton, PA 18509 Medicalresearch.com: What is the background for this study? Response: Prescription drugs have high levels of uniformity that plant-based products cannot achieve.  Given the liberalization of state-laws regarding medical marijuana1 over the past three-decades and increasing evidence of evidence of cannabis for conditions like chronic pain,2 we were interested in the use of the prescription formulation of delta(Δ)9-tetrahydrocannabinol (THC).  A prior pharmacoepidemiology report found that prescription THC (dronabinol) to Medicaid patients decreased from 2016 to 2020. There were also pronounced state-level disparities in prescribing with a 130-fold difference when correcting for population between the highest and lowest states. There was no research on this topic among Medicare patients. To address this gap, we obtained prescription numbers nationally and at a state level from 2014 to 2019 for Medicare Part D patients.

Infection prevention is often discussed in terms of cleaning protocols, hand hygiene, and clinical procedures, but the built environment also plays a direct role in how healthcare spaces function. Air conditions, moisture levels, pressure relationships, and mechanical system performance all affect the quality and consistency of the indoor environment. When those elements remain stable, facilities are better equipped to support patient care, protect sensitive spaces, and reduce conditions that allow contaminants to linger or spread. Environmental control matters because healthcare buildings operate under demands that go far beyond ordinary comfort. Patient rooms, treatment areas, support spaces, and specialized environments all rely on HVAC performance to maintain conditions appropriate for their use. Small shifts in humidity or airflow can create larger operational issues over time, especially in buildings with aging equipment or systems that are difficult to monitor closely. In many cases, problems begin quietly. A system may still be running, but coils may be losing efficiency, sensors may be providing poor readings, or controls may be drifting away from intended settings. Those changes can affect moisture removal, airflow consistency, and the ability of the space to perform as designed.

[caption id="attachment_73307" align="aligncenter" width="500"]weight-loss-myths.png Photo courtesy of Pexels[/caption] If you’ve ever looked up weight loss tips, you’ve probably seen a mix of advice that sounds convincing but doesn’t always hold up in real life. Just like you might check a healthy Costco snacks guide to make smarter choices, it’s just as important to filter out myths that can slow down your progress. Let’s break down some of the most common ones and what actually works instead. Let's break down some of the most common weight loss myths — and what actually works instead.

1. "Healthy" Packaged Foods Always Help With Weight Loss

Just because something is labeled "healthy" doesn't mean it's good for weight loss. Many packaged foods are still high in calories, sugar, or portion sizes that are easy to overeat. Even healthier options can slow progress if you're not mindful. Do your research on what healthy snacks are available — you can start by checking a healthy Costco snacks guide to understand better options and make more informed food choices. Check portion sizes rather than just labels, keep snacks simple (nuts, fruit, yogurt), and avoid mindless eating even with "healthy" foods.